REVIEW: New developments in the pharmacotherapy of cocaine abuse
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Despite huge advances in the neuroscience of substance abuse and dependence in the past 20 years, no approved pharmacological treatment exists for cocaine abuse. The available drugs for the treatment of cocaine abuse are poorly effective, hence the need for new compounds to be screened and tested for efficacy: targeting symptoms might improve the effectiveness of the treatment of cocaine abuse and dependence. On the basis of the known neurochemistry of cocaine, some target compounds have been studied: among others, BP‐897, a D3 partial agonist; vanoxerine, a highly selective inhibitor of dopamine uptake; aripiprazole, a partial mixed‐action agonist approved for the treatment of schizophrenia. Recently modafinil, approved for the treatment of narcolepsy, proved effective in favouring cocaine abstinence in cocaine‐abusing people. Some placebo‐controlled studies also reported the effectiveness of topiramate, a licensed antiepileptic drug, and of tiagabine, a gamma‐aminobutyric acid (GABA) re‐uptake inhibitor also approved as an anticonvulsant; both compounds increased cocaine abstinence with no serious adverse events. Promising results came from two more compounds acting on the GABA circuits, baclofen and valproic acid. Finally disulfiram, prescribed with active psychosocial therapy, was found to favour higher retention rates and longer abstinence periods from both alcohol and cocaine in polydrug‐abusing patients. An alternative approach rests on the use of vaccines, to date in the experimental stage still. Psychosocial treatments are a useful companion in the pharmacotherapy of cocaine abuse, with group therapy and contingency management therapies improving motivation and social functioning, particularly in patients abusing alcohol as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.11.1259 · Cited by 2,538
Endocrinology of the stress response
Charmandari, E., Tsigos, C., & Chrousos, G. (2005) · Annual Review of Physiology · doi:10.1146/annurev.physiol.67.040403.120816 · Cited by 1,799
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · cited 2×
“Valproic acid has multiple pharmacological actions, among others: the blockade of sodium channel and the inhibition of histone deacetylase, which can enhance glutamic acid decarboxylase activity, thus favouring the synthesis of GABA and potentiating GABA release and postsynaptic GABAergic response (Johannessen 2000; P…”
BackgroundKreek, M. J., Nielsen, D. A., Butelman, E. R., & LaForge, K. S. (2005) · Nature Neuroscience · doi:10.1038/nn1583 · Cited by 1,024
Neurobiology of relapse to heroin and cocaine seeking: a review
Shalev, U., Grimm, J. W., & Shaham, Y. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.1.1 · Cited by 880
Thomas, M. J., Beurrier, C., Bonci, A., & Malenka, R. C. (2001) · Nature Neuroscience · doi:10.1038/nn757 · Cited by 629
Sinha, R., Garcia, M., Paliwal, P., Kreek, M. J., & Rounsaville, B. J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.324 · Cited by 528 · cited 1×
“Some studies pointed that stress-related increases in cocaine craving and in hypothalamic–pituitary– adrenal axis responses are associated with specific cocaine relapse outcomes, such as time to relapse after detoxification and amount of use after relapse (Sinha et al. 2006).”
BackgroundAnticraving Medications for Relapse Prevention: A Possible New Class of Psychoactive Medications
O’Brien, C. P. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1423 · Cited by 405 · cited 6×
“The poor efficacy of currently available psychotropic drugs on the treatment of cocaine abuse urges new compounds to be screened and tested for efficacy (O’Brien 2005; Sofuoglu & Kosten 2005; Vocci & Ling 2005; Vocci et al .”
BackgroundInfluentialA Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391 · cited 2×
“…and psychiatric conditions found significantly more negative urine samples over the 8-week trial when compared with placebo, and a higher chance of achieving prolonged cocaine abstinence in the sample, with no serious adverse events and a high retention rate (no dropout) (Dackis et al. 2005).”
BackgroundThe Status of Disulfiram: A Half of a Century Later
Suh, J. J., Pettinati, H. M., Kampman, K. M., & O'Brien, C. P. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222512.25649.08 · Cited by 382
Cited by
Deficits in behavioural inhibition in substance abuse and addiction: a meta-analysis.
Smith, J. L., Mattick, R. P., Jamadar, S. D., & Iredale, J. M. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.009 · Cited by 546
Disulfiram for the treatment of cocaine dependence
Pani, P. P., Trogu, E., Vacca, R., Amato, L., Vecchi, S., & Davoli, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007024.pub2 · Cited by 255
Treatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
Nuijten, M., Blanken, P., van den Brink, W., & Hendriks, V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.02.024 · Cited by 38
Metadata
- Authors
- Preti, A.
- Venue
- Addiction Biology
- Publisher
- Wiley
- Published
- 2007-05-14
- Volume
- 12
- Issue
- 2
- Pages
- 133-151
- ISSN
- 1355-6215 (ISSN-L)
- 1369-1600
- OpenAlex
- W2142363976
- Cited by
- 79
- References
- 24
- FWCI
- 6.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: REVIEW: New developments in the pharmacotherapy of cocaine abuse. https://app.cochat.ai/papers/10.1111/j.1369-1600.2007.00061.x
- The paper
- Preti, A. (2007). REVIEW: New developments in the pharmacotherapy of cocaine abuse. Addiction Biology. https://doi.org/10.1111/j.1369-1600.2007.00061.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.